Early translational updates are emerging in oncology imaging and therapy, highlighted by new radioligand development and companion biomarker approaches. A double-target radioligand (INN02) reported preclinical antitumor imaging and an early clinical scan in the Journal of Translational Medicine, aiming to bind two tumor microenvironment hallmarks simultaneously. While still early, this line of work reflects a broader shift toward rationally designed imaging agents that can also support therapeutic intent. Separately, multiple studies point to improved triage and prognostic modeling using routine blood markers or simple scoring systems, potentially reducing dependence on invasive diagnostic pathways. For biotech professionals, the operational message is clear: imaging is becoming more tightly integrated with treatment selection, and novel agents are being developed with “theranostic” capabilities in mind. As these candidates move forward, the industry will watch how clinical scans translate into patient stratification, response prediction, and safety across targeted cohorts.